On Apr. 23, 2020, BioSig Technologies announced that an article titled, ﾓThe IMPDH inhibitor merimepodib has similar antiviral activity against SARS-CoV-2 replication in vitro to the adenosine analogue remdesivirﾔ was accepted by F1000 Research, an online peer-reviewed life sciences journal publishing program in biology and medicine.

The article highlighted emerging pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The work was started with Trek Therapeutics and after merimepodib was acquired by ViralClear has been continued by ViralClear.